MedTrace Logo

P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris

NCT02242760 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 213

Last updated 2023-05-31

Study results available
· View outcomes & findings →

Summary

This is a randomized, multi-center, double-blinded study in subjects with moderate to severe acne vulgaris. Subjects eligible to enroll will be treated once or twice daily with 2 concentrations of a topical drug in development or a vehicle. Subjects will be treated for up to 12 weeks.

Conditions

  • Acne Vulgaris

Interventions

DRUG

SB204 2%

Applied topically twice daily

DRUG

SB204 4%

Applied topically daily

DRUG

Vehicle Gel

Applied topically twice and once daily

Sponsors & Collaborators

  • Novan, Inc.

    lead INDUSTRY

Principal Investigators

  • M J Rico, MD · Novan, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2015-06-30
Completion
2015-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02242760 on ClinicalTrials.gov